Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Dermatologic 2Genitourinary 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 5Melanoma 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 5Cyclophosphamide 5Nivolumab 4Psychiatric Rehabilitation 3Paclitaxel 3Flow Cytometry 3Filgrastim 3valspodar 2sargramostim 2fludarabine 2epacadostat 2durvalumab 2atezolizumab 2aldesleukin 2Surveys and Questionnaires 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Interleukin-2 2Immunologic Techniques 2Early Intervention, Educational 2Dexamethasone 2Dasatinib 2Carboplatin 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × epacadostat × Gynecologic × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡